Roughly one in six adults across the globe faces challenges with fertility. Among the most frequent hurdles is irregular or completely absent ovulation. For decades, medical practitioners have relied on a medication known as clomiphene citrate as a cornerstone therapy to encourage egg release.
However, newly released research from the University of Adelaide, completed alongside specialists from Boston University and the Centers for Disease Control and Prevention (CDC), reveals critical safety concerns when patients accumulate higher amounts of the medication across multiple reproductive treatment rounds.
Landmark Investigation Examines Over 21,000 Treatment Cycles
The comprehensive observational investigation evaluated data from 21,004 in vitro fertilization (IVF) embryo transfer cycles within the United States. Researchers sought to evaluate how escalating aggregate levels of the medication influenced final clinical outcomes for expectant mothers and developing infants.
The findings indicate a clear relationship between dosage levels and reproductive complications. Individuals who took cumulative amounts between 500 and 749 milligrams experienced a 12 percent higher probability of pregnancy loss compared to those on baseline amounts.
For patients receiving aggregate quantities between 750 and 999 milligrams, the risk of miscarriage climbed by 38 percent. Furthermore, patients exposed to 750 milligrams or higher saw their chances of carrying multiple gestations—such as twins—more than double.
No Improvement in Successful Birth Rates
One of the most crucial insights from the analysis is that higher cumulative doses failed to yield higher rates of live births. While higher amounts did trigger more multiple gestations, twin and triplet pregnancies carry elevated medical risks for both mothers and newborns, including premature delivery and low birth weight.
Data revealed that spontaneous pregnancy loss rose steadily alongside increasing dosage tiers. Although researchers observed a higher rate of stillbirths at the most extreme dose levels, the small sample size in that rare bracket prevented the trend from reaching statistical certainty, indicating that further large-scale clinical trials remain necessary.
The findings align with earlier reproductive health papers from the University of Adelaide, which previously linked clomiphene citrate therapies to a doubled incidence of early infant loss.
A Longstanding Global Medication Under Fresh Scrutiny
Clomiphene citrate has served as a primary oral treatment for ovulatory dysfunction since its initial clinical debut in 1967. The World Health Organization (WHO) classifies the compound as an essential medication due to its broad accessibility and historical role in helping stimulate ovary function.
When individuals fail to ovulate at standard starting doses, or when they undergo multiple sequential treatment rounds over several months, cumulative exposure can rise substantially.
Study lead author Associate Professor Sheree Boulet emphasized that the data demonstrates a visible threshold where escalating intake brings diminishing clinical returns. Boulet noted that higher cumulative exposure steadily raised adverse pregnancy events without offering any meaningful boost in successful deliveries. Consequently, healthcare providers must carefully balance therapeutic benefits against potential hazards when structuring extended reproductive care plans.
Decades of Evidence Across Human and Animal Models
This latest study expands on extensive ongoing work conducted at the University of Adelaide’s Robinson Research Institute. Previous research programs have identified associations between the drug and elevated risks of pregnancy loss, perinatal mortality, and specific congenital anomalies.
Parallel laboratory studies in animal models reinforce these clinical observations. Controlled experiments in mice demonstrated that higher drug exposure reduced total successful pregnancies, impaired natural fetal growth, and correlated with elevated developmental abnormalities and embryonic loss.
Senior study investigator Professor Michael Davies noted that despite widespread use by millions of women over nearly sixty years, clomiphene citrate has rarely undergone comprehensive evaluation through massive modern prospective trials. Davies emphasized that individual biological responses vary widely and urged fertility specialists to adhere closely to established safety limits, avoiding unnecessary dosage escalations while researchers work to develop more personalized treatment protocols.
Why It Matters
These findings on clomiphene citrate safety are critical for prospective parents and reproductive endocrinologists evaluating first-line fertility treatments. Because escalating cumulative amounts increases the risk of miscarriage and complicated multiple births without boosting the overall likelihood of a healthy baby, clinicians must rethink aggressive multi-cycle dosing strategies. Understanding these medical thresholds allows physicians to tailor safer, individualized protocols, preventing avoidable pregnancy loss while ensuring reproductive care prioritizes maternal and neonatal safety above all else.
Sources / References
- Boulet, S., et al. “Dose-dependent perinatal risks of clomiphene citrate in US IVF cycles: a national cohort study, 2004–2021.” BMJ Open (2026). DOI: 10.1136/bmjopen-2025-115285.
- University of Adelaide, Robinson Research Institute, Perinatal Safety Research Archive.
- Centers for Disease Control and Prevention (CDC) Division of Reproductive Health & Boston University Collaborative Clinical Datasets.
